Hakan Kaya, MD | Authors

Trial Data Review: Selinexor, Carfilzomib, and Dexamethasone in R/R MM

October 13, 2022

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.